HARVARD BIOSCIENCE INC — Director's Dealing 2023

Mar 8, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HARVARD BIOSCIENCE INC (HBIO)
CIK: 0001123494
Period of Report: 2023-03-06

Reporting Person: Cote Jennifer (Interim CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-03-06	Common Stock	A	26892	$0.00	Acquired	57226	Direct
2023-03-06	Common Stock	A	25862	$0.00	Acquired	83088	Direct
2023-03-06	Common Stock	A	29880	$0.00	Acquired	112968	Direct

Footnotes

F1: Represents an award of 26,892 restricted stock units that will vest in three equal installments on December 29, 2023, 2024 and 2025, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person.

F2: Includes (a) the award described in footnote (1) above, (b) 22,342 restricted stock units that will vest in two equal installments on December 29, 2023 and 2024 and (c) 7,992 shares of common stock beneficially owned by the Reporting Person.

F3: Represents an award of 25,862 restricted stock units with performance based vesting conditions. These restricted stock units will vest upon the achievement of a relative total shareholder return of the Issuer's common stock during the period from March 1, 2023 to the earlier of (i) December 31, 2025, and (ii) the date of a change of control (the "Measurement Period"), measured relative to the Russell 2000 index and based on the 20-day trading average beginning on the first day of the Measurement Period and ending on the last day of the Measurement Period, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person. The target number of these restricted stock units that may be earned is reported above; the maximum amount is 150% of the number reported.

F4: Includes (a) the shares and awards described in footnote (2) above and (b) the award described in footnote (3) above.

F5: Represents an award of 29,880 restricted stock units that will fully vest on March 6, 2024.

F6: Includes (a) the shares and awards described in footnote (4) above and (b) the award described in footnote (5) above.